KIORA PHARMACEUTICALS INC (KPRX) Stock Price & Overview
NASDAQ:KPRX • US49721T5074
The current stock price of KPRX is 2.15 USD. Today KPRX is down by -0.92%. In the past month the price increased by 0.47%. In the past year, price decreased by -33.64%.
KPRX Key Statistics
- Market Cap
- 7.912M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.09
- Dividend Yield
- N/A
KPRX Stock Performance
KPRX Stock Chart
KPRX Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to KPRX. When comparing the yearly performance of all stocks, KPRX is a bad performer in the overall market: 81.2% of all stocks are doing better.
KPRX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to KPRX. The financial health of KPRX is average, but there are quite some concerns on its profitability.
KPRX Earnings
KPRX Forecast & Estimates
7 analysts have analysed KPRX and the average price target is 12.24 USD. This implies a price increase of 469.3% is expected in the next year compared to the current price of 2.15.
For the next year, analysts expect an EPS growth of -267.71% and a revenue growth -91.05% for KPRX
KPRX Groups
Sector & Classification
KPRX Financial Highlights
Over the last trailing twelve months KPRX reported a non-GAAP Earnings per Share(EPS) of -2.09. The EPS increased by 2.79% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -28.6% | ||
| ROE | -38.12% | ||
| Debt/Equity | 0 |
KPRX Ownership
KPRX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 27.96 | 943.209B | ||
| JNJ | JOHNSON & JOHNSON | 20.78 | 585.582B | ||
| MRK | MERCK & CO. INC. | 22.4 | 287.316B | ||
| PFE | PFIZER INC | 9 | 155.235B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.31 | 122.147B | ||
| ZTS | ZOETIS INC | 16.31 | 50.567B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.88 | 26.934B | ||
| VTRS | VIATRIS INC | 5.5 | 16.085B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.56 | 11.659B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.158B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.518B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 4.968B | ||
| LGND | LIGAND PHARMACEUTICALS | 24.91 | 4.412B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About KPRX
Company Profile
Kiora Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. The company is headquartered in Encinitas, California and currently employs 12 full-time employees. The company went IPO on 2015-02-13. The firm is engaged in developing KIO-301, a vision-restoring small molecule that acts as a photoswitch specifically created to restore vision in patients with inherited and age-related degenerative retinal diseases, including retinitis pigmentosa (RP). The company is also developing KIO-104 for the treatment of retinal inflammatory diseases, including Diabetic Macular Edema (DME) and Posterior Non-Infectious Uveitis, a rare T cell-mediated, intraocular inflammatory disease. KIO-104 is a non-steroidal small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH) formulated for intravitreal delivery and is ideally suited to suppressing overactive T-cell activity to treat the underlying inflammation. KIO-101 focuses on treating the ocular manifestation of patients with autoimmune diseases.
Company Info
IPO: 2015-02-13
KIORA PHARMACEUTICALS INC
169 Saxony Rd., Suite 212
Encinitas CALIFORNIA US
CEO: Franz Obermayr
Employees: 12
Phone: 13026365400
KIORA PHARMACEUTICALS INC / KPRX FAQ
What does KIORA PHARMACEUTICALS INC do?
Kiora Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. The company is headquartered in Encinitas, California and currently employs 12 full-time employees. The company went IPO on 2015-02-13. The firm is engaged in developing KIO-301, a vision-restoring small molecule that acts as a photoswitch specifically created to restore vision in patients with inherited and age-related degenerative retinal diseases, including retinitis pigmentosa (RP). The company is also developing KIO-104 for the treatment of retinal inflammatory diseases, including Diabetic Macular Edema (DME) and Posterior Non-Infectious Uveitis, a rare T cell-mediated, intraocular inflammatory disease. KIO-104 is a non-steroidal small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH) formulated for intravitreal delivery and is ideally suited to suppressing overactive T-cell activity to treat the underlying inflammation. KIO-101 focuses on treating the ocular manifestation of patients with autoimmune diseases.
What is the current price of KPRX stock?
The current stock price of KPRX is 2.15 USD. The price decreased by -0.92% in the last trading session.
Does KIORA PHARMACEUTICALS INC pay dividends?
KPRX does not pay a dividend.
What is the ChartMill rating of KIORA PHARMACEUTICALS INC stock?
KPRX has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Which stock exchange lists KPRX stock?
KPRX stock is listed on the Nasdaq exchange.
How many employees does KIORA PHARMACEUTICALS INC have?
KIORA PHARMACEUTICALS INC (KPRX) currently has 12 employees.